BioVertex Consulting was founded on a simple belief: life sciences companies deserve operational partners who understand the full journey, from early research through clinical development and regulatory submission.
Tanushree Phadke is a seasoned life sciences professional with over two decades of experience spanning research, program management, and strategic operations. Her journey has taken her through small biotech startups and large pharmaceutical companies in Boston, Massachusetts, and now extends to Singapore, where she founded BioVertex Consulting LLP.
Throughout her career, Tanushree has led cross-functional teams, advanced preclinical and early-stage clinical cell and gene therapy programs for rare diseases, and implemented fit-for-purpose portfolio and program management frameworks at companies including Tessera Therapeutics, Editas Medicine, Novartis, and Biogen. Notably, she brings over 5 years of hands-on experience with CRISPR/Cas9 gene editing technologies, working at the forefront of programmable genomic medicine at both Editas Medicine and Tessera Therapeutics, where she contributed to advancing next-generation gene writing and editing platforms from research through clinical development.
Her academic foundation includes a Master of Science in Biotechnology from Northeastern University (Boston, MA) and a Bachelor of Engineering in Biomedical from Mumbai University, graduating with distinction. She has pursued advanced coursework in genomics, epigenetics, cancer biology, and genome editing at Harvard Extension School, and holds a Project Management Professional (PMP) certification along with specialized training in biotechnology project management, drug development, high-performing teams, and GenAI.
At BioVertex Consulting, Tanushree brings a tailored, hands-on approach with a curated team of experienced consultants to help clients optimize R&D execution, streamline portfolio management, and enhance operational efficiency, bridging the gap between scientific innovation and business execution so that life sciences ventures achieve their milestones effectively and efficiently.
Tessera Therapeutics
Editas Medicine
Novartis
Biogen
US Genomics
MGI Pharma
We partner with a carefully curated network of industry experts who bring decades of specialized experience to our client engagements.
Specialized in regulatory documentation across the full development lifecycle, from IND through NDA/BLA. Experience spans anesthesia, CNS, immunology, oncology, pulmonary diseases, and rheumatology, including protocols, investigator brochures, clinical study reports, safety narratives, ISE/ISS/ISI, clinical overviews and summaries, and briefing documents.
Career spanning academia and industry with deep expertise in translational and preclinical sciences. Has guided companies from discovery through IND across autoimmune disease, immunology, and oncology, including target validation, mechanism-of-action studies, non-clinical development, and patient enrichment strategies. Dedicated to bridging early innovation with clinical impact.
The principles that guide every engagement, every recommendation, and every relationship.
Every decision we support is ultimately measured by its potential to bring better treatments to patients faster.
We don't deliver decks and walk away. We embed, we execute, and we stay accountable for outcomes.
Our team's foundation is deep scientific expertise. We bring technical credibility alongside operational discipline.
We help organizations do more with less, right-sizing frameworks, preserving runway, and maximizing every dollar invested.
With roots in the US and a base in Singapore, we bring a cross-border lens to development strategy and regulatory planning.
From Harvard coursework to GenAI training, we invest in staying at the frontier of science and technology.
Let's collaborate to bring groundbreaking solutions to patients worldwide. Whether you need program leadership, development strategy, or operational expertise, we're here to help.
Or email us directly: contactus@biovertexconsulting.com